Eton Pharmaceuticals (NASDAQ:ETON) said the FDA has extended the target action date for its market application for ET-400 to May 28 from Feb. 28. The company said it has been notified that the FDA will require more time to review supplemental information submitted at the agency's request in December.

Eton Pharmaceuticals (ETON) announced that the U.S. FDA has extended the Prescription Drug User Fee Act goal date for the New Drug Application

Eton Pharmaceuticals said the Food and Drug Administration has extended by three months its review of the company's application seeking approval of its ET-400 liquid formulation of hydrocortisone. Eton on Thursday said the FDA said it needs more time to review supplemental information the Deer Park,